HAEMONETICS CORP (HAE)
Health Care · Medical Devices & Supplies · NYSE
Haemonetics provides essential technologies for blood and plasma collection, as well as specialized medical devices for hospital procedures and hemostasis management.
What HAEMONETICS CORP does
Haemonetics is a global medical technology company that provides devices and software for blood and plasma collection and hospital-based procedural care. The company operates in three segments: Plasma, which provides systems and software for source plasma collection; Blood Center, which supplies collection devices for blood components; and Hospital, which offers interventional and hemostasis management technologies.
Themes: plasma collection / biopharmaceuticals, blood management / diagnostics, interventional hospital technologies
Fundamentals
- Price$119.47 as of 2026-10-08 close
- Market cap$5.4B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+134.3% 2025-10-08 close $50.98 → 2026-10-08 close $119.47
- P/E58.27 as of 2026-10-08
- Net margin+7.3% FY2026, SEC XBRL
- Gross margin+59.0% FY2026, SEC XBRL
- ROE+12.2% FY2026, SEC XBRL
- Debt / equity1.40 as of 2026-09-03
- Revenue growth (YoY)+0.4% as of 2026-09-03
- Revenue CAGR (3y)+4.5% SEC XBRL
- Beta0.55 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How HAE compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
HAE is not currently in any published Top 10 list. Its scores are below.
Top 10 score
49.9 #742 of 1,379 scored · #92 of 151 in Health Care
Trend 89th (it is 1.3% below its highest point of the past year) and capital return 56th (net share count bought back over the year 6.7, consecutive years of dividend increases 0 years); weakest is valuation (22nd, price to earnings 58.3, price to book 6.5).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How HAEMONETICS CORP looks technically
HAEMONETICS CORP (HAE) is trading 58.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 72 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 77, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is 1.3% below its 52-week high (its highest price of the past year). Trading volume is running unusually high — about 4.8× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 58.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +58.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $100.94 | $100.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $75.59 | $75.59 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 109.5707. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 72 trading days ago — a "golden cross", a bullish long-term signal | 72 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 27.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 77, in overbought territory (above 70) | 76.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($101.32 to $121.00) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 92.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $121.00 | $121.00 |
|---|---|---|
| From the 52-week high | it is 1.3% below its 52-week high (its highest price of the past year) | -1.3% |
| Above the 52-week low | it is 148.0% above its 52-week low (its lowest price of the past year) | +148.0% |
| Below the 52-week high | it is 1.3% below its highest point of the past year | 1.3% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $142.11 (set on 2021-02-09) | $142.11 |
| Given back of the 52-week move | over the past year its closes ranged ($48.58 to $119.47), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $73.39 to $75.66. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 15.9% below its all-time high | -15.9% |
| Nearest price level | it is trading 7.9% above a support level at $110.01 — a price it turned at twice since 2026-08-21, most recently on 2026-09-18. Since 2024-10-08 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -7.9% |
| All-time low | its lowest closing price on record is $19.58 (set on 2005-07-18) | $19.58 |
| Above the all-time low | it is 510.2% above its all-time low | +510.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 34th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.82 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.82 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $99.42 and $113.39 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $99.42 – $106.41 – $113.39 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 11.5 daily ranges above its 200-day average price (58.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 4.8× its 30-day average, a sign of heightened interest | 4.80× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 13.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +13.1% |
|---|---|---|
| Open gap | it gapped 13.1% above the previous close today and has not traded back through the level it left behind at 101.71 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +13.1% |
| Gap filled | a 2.0% gap up opened on 2026-09-17 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 15.1 percentage points (the stock gained 16.2% while the market gained 1.0%) | +15.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 58.0 percentage points (the stock gained 61.8% while the market gained 3.8%) | +58.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 86.9 percentage points (the stock gained 104.4% while the market gained 17.5%) | +86.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 119.4 percentage points (the stock gained 134.3% while the market gained 15.0%) | +119.4% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 19% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 8.0% of the share price. | +19.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 57% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $75.87 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +57.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $103.56 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | +15.4% |
Price levels it has turned at before
HAE last closed at $119.47 on 2026-10-08. Since 2024-10-08 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $110.01 | Support | 7.9% below the last close | turned there twice · 2026-08-21 to 2026-09-18 |
| $89.14 | Support | 25.4% below the last close | turned there twice · 2024-11-27 to 2026-08-03 |
| $86.70 | Support | 27.4% below the last close | turned there twice · 2025-12-10 to 2026-01-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $109.57.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $108.11 and $109.57 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.73 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$118.00 range $86.00 – $140.00; median $118.50
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HAE
- Consensus EPS estimate$1.29 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.00099 (+0.1%) from $1.29, on 2026-09-04, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["dependence on the plasma collection and fractionation industry market cycles","exposure to regulatory risks and changes in healthcare reimbursement policies","integration risks associated with past and future acquisitions"]
What changed in the latest 10-Q
AI-assisted comparison of HAE's 10-Q filed 2026-08-06 against the prior one filed 2026-02-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) added a 'Segment Organization Realignment' subsection under Recent Developments describing a June 5, 2026 reorganization into two segments (Apheresis and MedSurg), combining Plasma and Blood Center into Apheresis and renaming Hospital to MedSurg.
- Newer filing (2026-08-06) added a 'Revolving Credit Facility Repayment' subsection under Recent Developments describing borrowing $300.0 million in connection with convertible senior notes settlement, repaying $50.0 million in Q1 fiscal 2027, $250.0 million outstanding as of June 27, 2026, and an additional $50.0 million repayment in Q2 fiscal 2027.
- Newer filing (2026-08-06) changed the segment description in the Introduction from three reporting segments to two reporting segments (Apheresis and MedSurg).
- Newer filing (2026-08-06) changed references in the Introduction from 'Plasma,' 'Blood Center,' and 'Hospital' segment definitions to new 'Apheresis' and 'MedSurg' definitions.
- Newer filing (2026-08-06) changed the referenced Annual Report fiscal year from 'fiscal year ended March 29, 2025' to 'fiscal year ended March 28, 2026'.
- Removed:
- Older filing (2026-02-05) included a 'Recent Developments' subsection on the acquisition of Vivasure Medical Limited, which is absent from the newer filing.
- Older filing (2026-02-05) included a 'Recent Developments' subsection on Share Repurchases (360,457 shares for $25.0 million, $400.0 million remaining authorization), which is absent from the newer filing.
- Older filing (2026-02-05) included a paragraph under Introduction stating that Plasma and Hospital have the greatest growth potential and that Blood Center operates in more challenging markets, which is absent from the newer filing.
- Reworded:
- Newer filing (2026-08-06) revised the segment definitions in the Introduction; 'Apheresis' in the newer filing includes plasma collection devices and disposables for plasma, red cells and platelets, donor management software and supporting software solutions sold to plasma customers, and blood collection and processing devices, whereas the older filing (2026-02-05) had separate 'Plasma' and 'Blood Center' definitions.
- Newer filing (2026-08-06) described revenue growth as primarily from Apheresis (volume growth and share gains in Plasma) and MedSurg (share gains in Hemostasis Management and Transfusion Management), whereas older filing (2026-02-05) described revenue changes referencing Plasma, Blood Center, Hospital, CSL Plasma customer transition, and Whole Blood product line divestiture.
- Newer filing (2026-08-06) described operating income increase as due to favorable product mix and decreased amortization of fair value inventory step-up related to Attune Medical, whereas older filing (2026-02-05) attributed the operating income increase to pricing benefits, decreased restructuring costs, decreased Attune Medical step-up amortization, partially offset by lower gains on property, plant and equipment sales.
- Notes:
- The newer filing's Financial Summary and Results of Operations cover the three months ended June 27, 2026, while the older filing covers three and nine months ended December 27, 2025, so financial figures are not directly comparable between the two excerpts.
- The newer filing's MD&A excerpt is truncated mid-table in the Net Revenues by Business Unit section, limiting full comparison of that section.
Risk Factors
- Added:
- Newer filing (2026-08-06) adds reference to Annual Report on Form 10-K for fiscal year ended March 28, 2026 in Item 1A Risk Factors.
- Newer filing (2026-08-06) adds two new exhibits 10.1 and 10.2: Form of Performance Share Unit Award Agreement under Amended and Restated 2019 Long-Term Incentive Compensation Plan (adopted fiscal 2027) (rTSR) and (AAGR).
- Newer filing (2026-08-06) adds a footnote (1) in Exhibit list indicating these agreements relate to compensation of officers or directors.
- Removed:
- Older filing (2026-02-05) contains an Issuer Purchases of Equity Securities table with share repurchase data and footnotes, which is absent from newer filing.
- Older filing (2026-02-05) contains disclosure about a $500.0 million three-year share repurchase program approved April 2025, and a completed $75.0 million ASR with Citibank, which is absent from newer filing.
- Reworded:
- Item 1A Risk Factors: Newer filing (2026-08-06) references 'Annual Report on Form 10-K for the fiscal year ended March 28, 2026'; Older filing (2026-02-05) references 'Annual Report on Form 10-K for the fiscal year ended March 29, 2025.'
- Item 2: Newer filing (2026-08-06) states 'None.' Older filing (2026-02-05) contains the Issuer Purchases of Equity Securities table and related footnotes.
- Item 5: Newer filing (2026-08-06) references 'three months ended June 27, 2026'; Older filing (2026-02-05) references 'three months ended December 27, 2025.'
- Exhibit list: Newer filing (2026-08-06) references Form 10-Q for the quarter ended June 27, 2026; Older filing (2026-02-05) references quarter ended December 27, 2025.
- Notes:
- The provided texts include more than the Risk Factors section; comparisons reflect all items present in the submissions.
- Both Risk Factors sections state there are no material changes from the respective Annual Reports, so actual risk factor content is not provided for either filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2025-11-10. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about HAE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding HAE as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 11,285,871
- Reported value $846,440,326
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about HAE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
HAE had 3,424,696 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
HAE had 7.53% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.69 days to cover at the same settlement.
- Reported short interest (shares) 3,424,696
- Short interest (% of shares outstanding) 7.53%
- Prior settlement (shares) 2,863,501
- Reported change 19.6%
- Days to cover (reported) 5.69
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Terumo Blood and Cell Technologies
- Fresenius Kabi (FMS)
- Grifols (GRFS)
- CSL Limited (CSLLY)
- Baxter International (BAX)
- Edwards Lifesciences (EW)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HAE vs…
Frequently asked questions
What does HAEMONETICS CORP (HAE) do?
Haemonetics is a global medical technology company that provides devices and software for blood and plasma collection and hospital-based procedural care. The company operates in three segments: Plasma, which provides systems and software for source plasma collection; Blood Center, which supplies collection devices for blood components; and Hospital, which offers interventional and hemostasis management technologies.
What sector is HAEMONETICS CORP (HAE) in?
HAEMONETICS CORP (HAE) is classified in the Health Care sector. Its industry is Medical Devices & Supplies. It trades on NYSE.
Who are HAEMONETICS CORP's (HAE) competitors?
Notable peers of HAEMONETICS CORP (HAE) include Terumo Blood and Cell Technologies, Fresenius Kabi, Grifols, CSL Limited and Baxter International. This peer set is informational only — not financial advice.
Is HAEMONETICS CORP (HAE) overbought or oversold right now?
HAEMONETICS CORP (HAE) is currently in overbought territory (its 14-day RSI is 77, above 70) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HAE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.